Scientist, Discovery Oncology
Join a Team that Lives to Improve Lives
People come to Genentech from across disciplines and across the world to solve our most challenging medical conditions. You’ll find inspiration in our passion for biotechnology, our purpose to positively impact the lives of millions of patients and our dedication to our people. Joining Genentech means being part of a tradition of inquiry that will change the world. It means embracing our failures as much as our successes. It requires a willingness to look beyond the edge of what's possible. And a focus on doing the day-to-day work that makes great science happen.
The following opportunity exists in our South San Francisco, CA headquarters:
Scientist, Discovery Oncology
The Discovery Oncology department is seeking an exceptional, highly motivated and creative scientist to independently propose and lead innovative research efforts focused on RAS cancer biology within the department of Discovery Oncology. The ideal candidate will have significant experience in molecular biology, biochemistry, and signaling pathways using in vitro and/or in vivo model systems with a deep mechanistic understanding of how RAS oncogenes contribute to cancer development, tumor fitness, and evolution. The candidate may also have chemical biology, functional genomics, and computational experience relevant to RAS signaling. A solid track record of publications in top tier journals is required as is exceptional communication skills. The position will involve close collaboration with other research labs in Discovery Oncology as well as with other departments including Cancer Immunotherapy, Computational Biology, Translational Oncology, Functional Genomics and our core drug discovery groups.
The mission of Genentech’s Discovery Oncology department is to discover the next generation of oncology targets and therapeutics through in-depth interrogation of biological systems that will inform on tumor development, growth and signaling processes. We value scientists that take innovative approaches and delve deep into understanding the underlying mechanisms of cancer biology and therapeutic response, as it is essential to guide the optimal development of our therapies in the clinic. Our scientists are passionate about conducting groundbreaking science that can make a direct impact on patient’s lives. Examples of recent departmental publications include:
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, De Bruyn T, Giltnane JM, Hartman SJ, Heidersbach A, Houtman R, Ingalla E, Kategaya L, Kleinheinz T, Li J, Martin SE, Modrusan Z, Nannini M, Oeh J, Ubhayakar S, Wang X, Wertz IE, Young A, Yu M, Sampath D, Hager JH, Friedman LS, Daemen A, Metcalfe C. Cell. 2019 Aug 8;178(4):949-963.
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, La H, Zhang X, Martin SE, Lin E, Chan J, Yu Y, Amin D, Neve RM, Gustafson A, Venkatanarayan A, Foster SA, Rudolph J, Klijn C, Malek S. Cancer Cell. 2018 Oct 8;34(4):611-625.
The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.
Hagenbeek TJ, Webster JD, Kljavin NM, Chang MT, Pham T, Lee HJ, Klijn C, Cai AG, Totpal K, Ravishankar B, Yang N, Lee DH, Walsh KB, Hatzivassiliou G, de la Cruz CC, Gould SE, Wu X, Lee WP, Yang S, Zhang Z, Gu Q, Ji Q, Jackson EL, Lim DS, Dey A. Sci Signal. 2018 Sep 11;11(547).
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, Flynn EM, Romero FA, Magnuson S, Gascoigne KE. Cell Rep. 2018 Aug 14;24(7):1722-1729.
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.
Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, Firestein R, Latham S, Sampath D, Evangelista M, Hatzivassiliou G. Cell Metab. 2018 Sep 4;28(3):383-399.
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Dompe N, Klijn C, Watson SA, Leng K, Port J, Cuellar T, Watanabe C, Haley B, Neve R, Evangelista M, Stokoe D. PLoS One. 2018 Jun 18;13(6):e0199264. doi: 10.1371/journal.pone.0199264.
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. Cell. 2017 Feb 23;168(5):817-829.
Who You Are
- A Ph.D. in Biochemistry, Cell Biology or a related field is required with 3-6 years of relevant post-doctoral research experience.
- Candidates with 8-10 years of academic experience and/or industry experience with extensive experience with target validation and drug development in cancer biology especially in the RAS field are encouraged to apply.
- Applicants should have experience in areas of cancer cell biology, molecular biology, biochemistry, cancer genomics.
- A strong track record of cutting edge research as evidenced by recent senior corresponding authored publications in top tier journals is required.
- Outstanding written and oral communication skills are essential as is the ability to lead a laboratory group and oversee research programs across cross-functional research teams.
A Job with Benefits Beyond the Benefits
A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
The next step is yours. To apply today, click on the "Apply online" button.
Genentech is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. For more information about equal employment opportunity, visit our Genentech Careers page.
At Genentech, we share salary ranges with applicants during the recruiting process, if requested. Third party salary estimates may not be accurate or up-to-date.